GRFS
Grifols SA ADR
NASDAQ: GRFS · HEALTHCARE · DRUG MANUFACTURERS - GENERAL
$7.80
+0.79% today
Updated 2026-06-05
Market cap
$5.20B
P/E ratio
10.91
P/S ratio
0.70x
EPS (TTM)
$0.70
Dividend yield
2.30%
52W range
$7 – $11
Volume
0.7M
WallStSmart proprietary scores
69
out of 100
Grade: B
Buy
Investment rating
6.0
Growth
B5.5
Quality
C+5.5
Profitability
C+9.3
Valuation
A+4/9
Piotroski F-Score
Moderate
1.2
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$10.87
+39.36%
12-Month target
$9.35
+19.87%
Intrinsic (DCF)
$12.03
Margin of safety
+23.44%
0 Strong Buy1 Buy1 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Free cash flow $58.95M — positive
+ 23.44% below intrinsic value
Risks
- Altman Z 1.15 — distress zone
- Revenue declining -4.80% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $6.06B | $6.59B | $7.21B | $7.23B | $7.44B |
| Net income | $185.03M | $42.32M | $156.92M | $386.13M | $74.20M |
| EPS | — | — | — | — | $0.70 |
| Free cash flow | $-386.43M | $-91.63M | $530.80M | $751.14M | $58.95M |
| Profit margin | 3.05% | 0.64% | 2.18% | 5.34% | 5.58% |
Peer comparison
Smart narrative
Grifols SA ADR trades at $7.80. representing a P/E of 10.91x trailing earnings. Our Smart Value Score of 69/100 indicates the stock is good. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of 1.15, it sits in the distress. TTM revenue stands at $7.44B. with profit margins at 5.58%. Our DCF model estimates intrinsic value at $12.03.
Frequently asked questions
What is Grifols SA ADR's stock price?
Grifols SA ADR (GRFS) trades at $7.80, on a P/E of 10.9x and a P/S of 0.7x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Grifols SA ADR overvalued?
Grifols SA ADR carries a Smart Value Score of 69/100 (Grade B), which we rate Buy. That score blends growth, quality, and valuation into one read. Our DCF puts intrinsic value at $12.03 versus the $7.80 price, a 23.4% margin of safety on a cash flow basis.
What is the price target of Grifols SA ADR (GRFS)?
The 12-month analyst consensus target is $10.87, about 39.4% above the current $7.80. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the intrinsic value of Grifols SA ADR (GRFS)?
Our DCF model estimates intrinsic value at $12.03, a +23.4% margin of safety versus today's $7.80. Intrinsic value is what the projected cash flows are worth today. A positive reading means the price sits below that estimate, leaving a cushion if growth holds.
What is Grifols SA ADR's revenue?
Grifols SA ADR's trailing twelve-month revenue is $7.44B. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Grifols SA ADR's Altman Z-Score is 1.15, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - GENERAL
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio0.70x
ROE7.61%
Beta1.17
50D MA$8.01
200D MA$8.82
Shares out0.68B
Float0.83B
Short ratio—
Avg volume0.7M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—